Global HIV Drugs Market Size study, By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors), and Regional Forecasts 2020-2027
Global HIV Drugs Market is valued approximately at USD 30.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2020-2027. Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease that can be transmitted from one person to another through blood-to-blood and sexual contact. It is a virus that destroys immune cells known as CD-4 cells, rendering the body vulnerable to infections and other diseases. Over the years, the growing prevalence of HIV disease worldwide has had a positive effect on demand for HIV drugs. HIV medications help prevent the spread of HIV, thereby reducing the risk of transmission of HIV. Significant factors that fuel the growth of the HIV drug market include an increase in HIV prevalence and an increase in the rate of care and diagnosis. In addition, there is an increase in government initiatives to raise awareness among people about the cause of HIV, symptoms, available treatment options, and the critical role of these treatments in controlling the growth of the HIV virus. As a result, awareness-raising through such government programs is also expected to improve the demand for HIV drugs. However, strict government regulations for the approval and sale of HIV drugs are likely to limit the development of the HIV drug industry. The factors responsible for increasing prevalence include unsafe sex, infected needles or syringes, and, lack of knowledge of the mode of transmission. The concerted efforts of the government and various NGOs to provide at-risk individuals with greater exposure to disease testing and care for infected persons are a key driver of the growth of the HIV-1 industry. In addition, the advent of generic drugs, which are cost-effective and chemically like branded drugs, is another factor adding to the demand for HIV drugs. According to WHO, 37.9 million people were diagnosed with HIV/AIDS in 2018, globally, while 1.1 million died of AIDS-related illness in the same year. A variety of community awareness programmes and education campaigns have been initiated by federal government agencies and numerous organizations across the globe to combat HIV prevention, treatment and care.
The regional analysis of global HIV Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific offers lucrative prospects for key players on the HIV drug market due to a rise in population and a high increase in geriatric population. In addition, the increase in health expenditure and the production of guidelines are expected to fuel market growth in the region.
Major market player included in this report are:
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences, Inc.
Johnson & Johnson
Cipla Limited
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Medication Class:
Multi-class Combination Drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (P0Is)
Entry Inhibitors
HIV Integrase Strand Transfer Inhibitors
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global HIV Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
The regional analysis of global HIV Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific offers lucrative prospects for key players on the HIV drug market due to a rise in population and a high increase in geriatric population. In addition, the increase in health expenditure and the production of guidelines are expected to fuel market growth in the region.
Major market player included in this report are:
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences, Inc.
Johnson & Johnson
Cipla Limited
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Medication Class:
Multi-class Combination Drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (P0Is)
Entry Inhibitors
HIV Integrase Strand Transfer Inhibitors
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global HIV Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. HIV Drugs Market, by Region, 2018-2027 (USD Billion)
1.2.2. HIV Drugs Market, by Medication Class, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL HIV DRUGS MARKET DEFINITION & SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL HIV DRUGS MARKET DYNAMICS
3.1. HIV Drugs Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. GLOBAL HIV DRUGS MARKET: INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS
5.1. Market Snapshot
5.2. Global HIV Drugs Market by Medication Class, Performance - Potential Analysis
5.3. Global HIV Drugs Market Estimates & Forecasts by Medication Class, 2017-2027 (USD Billion)
5.4. HIV Drugs Market, Sub Segment Analysis
5.4.1. Multi-class Combination Drugs
5.4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.4.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.4.4. Protease Inhibitors (P0Is)
5.4.5. Entry Inhibitors
5.4.6. HIV Integrase Strand Transfer Inhibitors
CHAPTER 6. GLOBAL HIV DRUGS MARKET, REGIONAL ANALYSIS
6.1. HIV Drugs Market, Regional Market Snapshot
6.2. North America HIV Drugs Market
6.2.1. U.S. HIV Drugs Market
6.2.1.1. Medication Class breakdown estimates & forecasts, 2017-2027
6.2.2. Canada HIV Drugs Market
6.3. Europe HIV Drugs Market Snapshot
6.3.1. U.K. HIV Drugs Market
6.3.2. Germany HIV Drugs Market
6.3.3. France HIV Drugs Market
6.3.4. Spain HIV Drugs Market
6.3.5. Italy HIV Drugs Market
6.3.6. Rest of Europe HIV Drugs Market
6.4. Asia-Pacific HIV Drugs Market Snapshot
6.4.1. China HIV Drugs Market
6.4.2. India HIV Drugs Market
6.4.3. Japan HIV Drugs Market
6.4.4. Australia HIV Drugs Market
6.4.5. South Korea HIV Drugs Market
6.4.6. Rest of Asia Pacific HIV Drugs Market
6.5. Latin America HIV Drugs Market Snapshot
6.5.1. Brazil HIV Drugs Market
6.5.2. Mexico HIV Drugs Market
6.6. Rest of The World HIV Drugs Market
CHAPTER 7. COMPETITIVE INTELLIGENCE
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Boehringer Ingelheim International GmbH
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Industry Summary
7.2.1.5. Recent Developments
7.2.2. Merck & Co., Inc.
7.2.3. ViiV Healthcare
7.2.4. AbbVie
7.2.5. F. Hoffmann-La Roche Ltd.
7.2.6. Teva Pharmaceutical Industries Ltd.
7.2.7. Bristol-Myers Squibb
7.2.8. Gilead Sciences, Inc.
7.2.9. Johnson & Johnson
7.2.10. Cipla Limited
7.2.11. Daiichi Sankyo
7.2.12. Emcure
7.2.13. Hetero Drugs
7.2.14. Mylan
CHAPTER 8. RESEARCH PROCESS
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. HIV Drugs Market, by Region, 2018-2027 (USD Billion)
1.2.2. HIV Drugs Market, by Medication Class, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL HIV DRUGS MARKET DEFINITION & SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL HIV DRUGS MARKET DYNAMICS
3.1. HIV Drugs Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. GLOBAL HIV DRUGS MARKET: INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS
5.1. Market Snapshot
5.2. Global HIV Drugs Market by Medication Class, Performance - Potential Analysis
5.3. Global HIV Drugs Market Estimates & Forecasts by Medication Class, 2017-2027 (USD Billion)
5.4. HIV Drugs Market, Sub Segment Analysis
5.4.1. Multi-class Combination Drugs
5.4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.4.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.4.4. Protease Inhibitors (P0Is)
5.4.5. Entry Inhibitors
5.4.6. HIV Integrase Strand Transfer Inhibitors
CHAPTER 6. GLOBAL HIV DRUGS MARKET, REGIONAL ANALYSIS
6.1. HIV Drugs Market, Regional Market Snapshot
6.2. North America HIV Drugs Market
6.2.1. U.S. HIV Drugs Market
6.2.1.1. Medication Class breakdown estimates & forecasts, 2017-2027
6.2.2. Canada HIV Drugs Market
6.3. Europe HIV Drugs Market Snapshot
6.3.1. U.K. HIV Drugs Market
6.3.2. Germany HIV Drugs Market
6.3.3. France HIV Drugs Market
6.3.4. Spain HIV Drugs Market
6.3.5. Italy HIV Drugs Market
6.3.6. Rest of Europe HIV Drugs Market
6.4. Asia-Pacific HIV Drugs Market Snapshot
6.4.1. China HIV Drugs Market
6.4.2. India HIV Drugs Market
6.4.3. Japan HIV Drugs Market
6.4.4. Australia HIV Drugs Market
6.4.5. South Korea HIV Drugs Market
6.4.6. Rest of Asia Pacific HIV Drugs Market
6.5. Latin America HIV Drugs Market Snapshot
6.5.1. Brazil HIV Drugs Market
6.5.2. Mexico HIV Drugs Market
6.6. Rest of The World HIV Drugs Market
CHAPTER 7. COMPETITIVE INTELLIGENCE
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Boehringer Ingelheim International GmbH
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Industry Summary
7.2.1.5. Recent Developments
7.2.2. Merck & Co., Inc.
7.2.3. ViiV Healthcare
7.2.4. AbbVie
7.2.5. F. Hoffmann-La Roche Ltd.
7.2.6. Teva Pharmaceutical Industries Ltd.
7.2.7. Bristol-Myers Squibb
7.2.8. Gilead Sciences, Inc.
7.2.9. Johnson & Johnson
7.2.10. Cipla Limited
7.2.11. Daiichi Sankyo
7.2.12. Emcure
7.2.13. Hetero Drugs
7.2.14. Mylan
CHAPTER 8. RESEARCH PROCESS
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption
LIST OF TABLES
TABLE 1. GLOBAL HIV DRUGS MARKET, REPORT SCOPE
TABLE 2. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
TABLE 3. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY MEDICATION CLASS 2017-2027 (USD BILLION)
TABLE 4. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 5. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 6. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 7. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 8. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 9. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 11. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 13. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 14. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 15. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 16. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 17. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 18. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 19. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 20. UK HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 21. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 22. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 23. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 24. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 25. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 26. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 27. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 28. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 29. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 30. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 31. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 32. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 33. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 34. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 35. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 36. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 37. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 38. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 39. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 40. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 41. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 42. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 43. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 44. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 45. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 46. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 47. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 48. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 49. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 50. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 51. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 52. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 53. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
TABLE 54. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
TABLE 55. YEARS CONSIDERED FOR THE STUDY
TABLE 56. EXCHANGE RATES CONSIDERED
TABLE 1. GLOBAL HIV DRUGS MARKET, REPORT SCOPE
TABLE 2. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
TABLE 3. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY MEDICATION CLASS 2017-2027 (USD BILLION)
TABLE 4. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 5. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 6. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 7. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 8. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 9. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 11. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 13. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 14. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 15. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 16. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 17. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 18. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 19. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 20. UK HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 21. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 22. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 23. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 24. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 25. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 26. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 27. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 28. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 29. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 30. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 31. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 32. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 33. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 34. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 35. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 36. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 37. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 38. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 39. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 40. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 41. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 42. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 43. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 44. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 45. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 46. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 47. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 48. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 49. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 50. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
TABLE 51. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 52. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
TABLE 53. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
TABLE 54. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
TABLE 55. YEARS CONSIDERED FOR THE STUDY
TABLE 56. EXCHANGE RATES CONSIDERED
LIST OF FIGURES
FIG 1. GLOBAL HIV DRUGS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL HIV DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL HIV DRUGS MARKET, KEY TRENDS 2019
FIG 5. GLOBAL HIV DRUGS MARKET, GROWTH PROSPECTS 2020-2027
FIG 6. GLOBAL HIV DRUGS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL HIV DRUGS MARKET, PEST ANALYSIS
FIG 8. GLOBAL HIV DRUGS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 11. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 13. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 14. GLOBAL HIV DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
FIG 15. NORTH AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 16. EUROPE HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 17. ASIA PACIFIC HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 18. LATIN AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 19. GLOBAL HIV DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
FIG 1. GLOBAL HIV DRUGS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL HIV DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL HIV DRUGS MARKET, KEY TRENDS 2019
FIG 5. GLOBAL HIV DRUGS MARKET, GROWTH PROSPECTS 2020-2027
FIG 6. GLOBAL HIV DRUGS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL HIV DRUGS MARKET, PEST ANALYSIS
FIG 8. GLOBAL HIV DRUGS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 11. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 13. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
FIG 14. GLOBAL HIV DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
FIG 15. NORTH AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 16. EUROPE HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 17. ASIA PACIFIC HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 18. LATIN AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
FIG 19. GLOBAL HIV DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
